(MDT) Medtronic - Overview
Exchange: NYSE •
Country: Ireland •
Currency: USD •
Type: Common Stock •
ISIN: IE00BTN1Y115
Stock: Pacemakers, Defibrillators, Valves, Stents, Pumps
Total Rating 50
Risk 89
Buy Signal -1.22
| Risk 5d forecast | |
|---|---|
| Volatility | 21.6% |
| Relative Tail Risk | -5.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.00 |
| Alpha | -6.10 |
| Character TTM | |
|---|---|
| Beta | 0.333 |
| Beta Downside | 0.124 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.77% |
| CAGR/Max DD | 0.42 |
EPS (Earnings per Share)
Revenue
Description: MDT Medtronic February 27, 2026
Medtronic plc (NYSE: MDT) is a global leader in device-based medical therapies, operating across four main portfolios: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company designs and sells a broad array of products-from implantable cardiac devices and aortic valves to spinal cord stimulators, robotic-assisted surgical tools, and continuous glucose monitoring systems-serving hospitals, physicians, and patients worldwide.
In its most recent fiscal year (2023), Medtronic generated $31.7 billion in revenue, with an operating margin of 27% and earnings per share of $8.70. R&D spending reached $2.2 billion, reflecting a continued focus on next-generation minimally invasive technologies. The firm’s growth is bolstered by macro-drivers such as an aging global population, rising prevalence of chronic diseases, and sustained U.S. healthcare spending growth of roughly 5% YoY.
For a deeper dive, you might explore ValueRay’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 4.61b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.16 > 1.0 |
| NWC/Revenue: 41.08% < 20% (prev 32.15%; Δ 8.93% < -1%) |
| CFO/TA 0.08 > 3% & CFO 7.29b > Net Income 4.61b |
| Net Debt (26.92b) to EBITDA (9.36b): 2.88 < 3 |
| Current Ratio: 2.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.16% < -2% |
| Gross Margin: 61.95% > 18% (prev 0.65%; Δ 6130 % > 0.5%) |
| Asset Turnover: 39.11% > 50% (prev 36.90%; Δ 2.21% > 0%) |
| Interest Coverage Ratio: 8.81 > 6 (EBITDA TTM 9.36b / Interest Expense TTM 712.0m) |
Altman Z'' 3.35
| A: 0.16 (Total Current Assets 24.07b - Total Current Liabilities 9.49b) / Total Assets 91.48b |
| B: 0.35 (Retained Earnings 32.30b / Total Assets 91.48b) |
| C: 0.07 (EBIT TTM 6.27b / Avg Total Assets 90.73b) |
| D: 0.66 (Book Value of Equity 27.79b / Total Liabilities 42.29b) |
| Altman-Z'' Score: 3.35 = A |
Beneish M -3.78
| DSRI: 0.01 (Receivables 87.0m/6.12b, Revenue 35.48b/33.20b) |
| GMI: 1.05 (GM 61.95% / 65.27%) |
| AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 35.48b / 33.20b) |
| TATA: -0.03 (NI 4.61b - CFO 7.29b) / TA 91.48b) |
| Beneish M-Score: -3.78 (Cap -4..+1) = AAA |
What is the price of MDT shares?
As of March 07, 2026, the stock is trading at USD 93.01 with a total of 8,367,280 shares traded.
Over the past week, the price has changed by -4.14%, over one month by -9.66%, over three months by -7.56% and over the past year by +2.00%.
Over the past week, the price has changed by -4.14%, over one month by -9.66%, over three months by -7.56% and over the past year by +2.00%.
Is MDT a buy, sell or hold?
Medtronic has received a consensus analysts rating of 3.81.
Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the MDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 111.7 | 20.1% |
| Analysts Target Price | 111.7 | 20.1% |
MDT Fundamental Data Overview March 06, 2026
P/E Trailing = 26.7039
P/E Forward = 15.9236
P/S = 3.459
P/B = 2.5347
P/EG = 1.6949
Revenue TTM = 35.48b USD
EBIT TTM = 6.27b USD
EBITDA TTM = 9.36b USD
Long Term Debt = 27.82b USD (from longTermDebt, last quarter)
Short Term Debt = 191.0m USD (from shortTermDebt, last quarter)
Debt = 28.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 26.92b USD (from netDebt column, last quarter)
Enterprise Value = 142.43b USD (122.74b + Debt 28.07b - CCE 8.38b)
Interest Coverage Ratio = 8.81 (Ebit TTM 6.27b / Interest Expense TTM 712.0m)
EV/FCF = 26.33x (Enterprise Value 142.43b / FCF TTM 5.41b)
FCF Yield = 3.80% (FCF TTM 5.41b / Enterprise Value 142.43b)
FCF Margin = 15.25% (FCF TTM 5.41b / Revenue TTM 35.48b)
Net Margin = 13.00% (Net Income TTM 4.61b / Revenue TTM 35.48b)
Gross Margin = 61.95% ((Revenue TTM 35.48b - Cost of Revenue TTM 13.50b) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.32%)
Tobins Q-Ratio = 1.56 (Enterprise Value 142.43b / Total Assets 91.48b)
Interest Expense / Debt = 0.64% (Interest Expense 181.0m / Debt 28.07b)
Taxrate = 18.09% (254.0m / 1.40b)
NOPAT = 5.14b (EBIT 6.27b * (1 - 18.09%))
Current Ratio = 2.54 (Total Current Assets 24.07b / Total Current Liabilities 9.49b)
Debt / Equity = 0.57 (Debt 28.07b / totalStockholderEquity, last quarter 48.98b)
Debt / EBITDA = 2.88 (Net Debt 26.92b / EBITDA 9.36b)
Debt / FCF = 4.98 (Net Debt 26.92b / FCF TTM 5.41b)
Total Stockholder Equity = 48.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.09% (Net Income 4.61b / Total Assets 91.48b)
RoE = 9.54% (Net Income TTM 4.61b / Total Stockholder Equity 48.39b)
RoCE = 8.23% (EBIT 6.27b / Capital Employed (Equity 48.39b + L.T.Debt 27.82b))
RoIC = 6.68% (NOPAT 5.14b / Invested Capital 76.91b)
WACC = 6.29% (E(122.74b)/V(150.81b) * Re(7.61%) + D(28.07b)/V(150.81b) * Rd(0.64%) * (1-Tc(0.18)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.05%
[DCF] Terminal Value 84.90% ; FCFF base≈5.43b ; Y1≈5.52b ; Y5≈6.04b
[DCF] Fair Price = 102.9 (EV 159.09b - Net Debt 26.92b = Equity 132.17b / Shares 1.28b; r=6.29% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 20.72 | EPS CAGR: -2.92% | SUE: 2.12 | # QB: 5
Revenue Correlation: 79.82 | Revenue CAGR: 2.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-07-31): EPS=1.38 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=22
EPS next Year (2027-04-30): EPS=6.10 | Chg7d=-0.002 | Chg30d=-0.026 | Revisions Net=-13 | Growth EPS=+8.0% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: +0.08 (7 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.2% (Discount Rate 7.9% - Earnings Yield 3.7%)
[Growth] Growth Spread = +5.2% (Analyst 9.4% - Implied 4.2%)
P/E Forward = 15.9236
P/S = 3.459
P/B = 2.5347
P/EG = 1.6949
Revenue TTM = 35.48b USD
EBIT TTM = 6.27b USD
EBITDA TTM = 9.36b USD
Long Term Debt = 27.82b USD (from longTermDebt, last quarter)
Short Term Debt = 191.0m USD (from shortTermDebt, last quarter)
Debt = 28.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 26.92b USD (from netDebt column, last quarter)
Enterprise Value = 142.43b USD (122.74b + Debt 28.07b - CCE 8.38b)
Interest Coverage Ratio = 8.81 (Ebit TTM 6.27b / Interest Expense TTM 712.0m)
EV/FCF = 26.33x (Enterprise Value 142.43b / FCF TTM 5.41b)
FCF Yield = 3.80% (FCF TTM 5.41b / Enterprise Value 142.43b)
FCF Margin = 15.25% (FCF TTM 5.41b / Revenue TTM 35.48b)
Net Margin = 13.00% (Net Income TTM 4.61b / Revenue TTM 35.48b)
Gross Margin = 61.95% ((Revenue TTM 35.48b - Cost of Revenue TTM 13.50b) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.32%)
Tobins Q-Ratio = 1.56 (Enterprise Value 142.43b / Total Assets 91.48b)
Interest Expense / Debt = 0.64% (Interest Expense 181.0m / Debt 28.07b)
Taxrate = 18.09% (254.0m / 1.40b)
NOPAT = 5.14b (EBIT 6.27b * (1 - 18.09%))
Current Ratio = 2.54 (Total Current Assets 24.07b / Total Current Liabilities 9.49b)
Debt / Equity = 0.57 (Debt 28.07b / totalStockholderEquity, last quarter 48.98b)
Debt / EBITDA = 2.88 (Net Debt 26.92b / EBITDA 9.36b)
Debt / FCF = 4.98 (Net Debt 26.92b / FCF TTM 5.41b)
Total Stockholder Equity = 48.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.09% (Net Income 4.61b / Total Assets 91.48b)
RoE = 9.54% (Net Income TTM 4.61b / Total Stockholder Equity 48.39b)
RoCE = 8.23% (EBIT 6.27b / Capital Employed (Equity 48.39b + L.T.Debt 27.82b))
RoIC = 6.68% (NOPAT 5.14b / Invested Capital 76.91b)
WACC = 6.29% (E(122.74b)/V(150.81b) * Re(7.61%) + D(28.07b)/V(150.81b) * Rd(0.64%) * (1-Tc(0.18)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.05%
[DCF] Terminal Value 84.90% ; FCFF base≈5.43b ; Y1≈5.52b ; Y5≈6.04b
[DCF] Fair Price = 102.9 (EV 159.09b - Net Debt 26.92b = Equity 132.17b / Shares 1.28b; r=6.29% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 20.72 | EPS CAGR: -2.92% | SUE: 2.12 | # QB: 5
Revenue Correlation: 79.82 | Revenue CAGR: 2.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-07-31): EPS=1.38 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=22
EPS next Year (2027-04-30): EPS=6.10 | Chg7d=-0.002 | Chg30d=-0.026 | Revisions Net=-13 | Growth EPS=+8.0% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: +0.08 (7 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.2% (Discount Rate 7.9% - Earnings Yield 3.7%)
[Growth] Growth Spread = +5.2% (Analyst 9.4% - Implied 4.2%)